person · Reporting owner

KINDLER JEFFREY B

Disclosed activity across 8 companies

Tapewire entity: 16924
SEC CIK: 0001174454

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
PERRIGO Co plcPRGO · Entity 4516	Director	May 14, 2025	May 16, 2025
PRECIGEN, INC.PGEN · Entity 4356	Director	August 26, 2026	August 28, 2026
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026
SIGA TECHNOLOGIES INCSIGA · Entity 6205	Director	May 21, 2020	May 22, 2020
vTv Therapeutics Inc.VTVT · Entity 6614	Director	June 11, 2020	June 15, 2020

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

PERRIGO Co plc

Report date May 14, 2025 · Filed May 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	10,559	Ending reported balance After 2025-05-14 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2025-05-14 · Exercise / conversion · Acquired 9,904 · Balance 15,313 Row 2 · 2025-05-14 · Tax withholding · Disposed 4,754 · Balance 10,559
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	7,305	Reported balance After 2025-05-14 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2025-05-14 · Grant · Acquired 7,305 · Balance 7,305 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2025-05-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2025-05-14 · Exercise / conversion · Disposed 9,904 · Balance 0 F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

Filing footnotes · ownership attribution and instrument terms

F1: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share.

F2: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2026.

F3: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Vesting on 14 May 2025.

PRECIGEN, INC.

Report date August 26, 2026 · Filed August 28, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	17,100	Reported balance After 2026-08-26 transaction · row 1 1 source row Row 1 · 2026-08-26 · Sale · Disposed 185,000 · Balance 17,100 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.38 to $7.59, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (1) to this Form 4.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,537	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 2,537 F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Kindler was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

SIGA TECHNOLOGIES INC

Report date May 21, 2020 · Filed May 22, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, Par Value $.0001 Per ShareSEC Table I · non-derivative	Direct	127,339	Reported balance After 2020-05-21 transaction · row 1 1 source row Row 1 · 2020-05-21 · Exercise / conversion · Acquired 15,000 · Balance 127,339
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-05-21 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-05-21 · Exercise / conversion · Disposed 15,000 · Balance 0 F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis.

F2: The RSUs were granted on May 21, 2019, and vested on the first anniversary of such date.

vTv Therapeutics Inc.

Report date June 11, 2020 · Filed June 15, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Director stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.65 · Expires 2030-06-11	Direct	78,121	Reported balance After 2020-06-11 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2020-06-11 · Grant · Acquired 15,000 · Balance 78,121 F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

Filing footnotes · ownership attribution and instrument terms

F1: The option vests in monthly equal installments over the three year period beginning on June 11, 2020.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PFIZER INC

Report date December 15, 2010 · Filed December 17, 2010

Section 16 reporting ended · disclosed 2010-12-17. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Phantom Stock Units SSPSEC Table II · derivative / convertible security	Direct	62,194	Reported balance After 2010-12-15 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2010-12-15 · Grant · Acquired 261 · Balance 62,194 F1: Each unit represents one phantom share of common stock. F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

Filing footnotes · ownership attribution and instrument terms

F1: Each unit represents one phantom share of common stock.

F2: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

PPD, Inc.

Report date December 08, 2021 · Filed December 08, 2021

Section 16 reporting ended · disclosed 2021-12-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2021-12-08 transaction · row 1 1 source row Row 1 · 2021-12-08 · Disposition to issuer · Disposed 99,487 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").
Common StockSEC Table I · non-derivative	IndirectBy Trust	0	Reported balance After 2021-12-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 2 · 2021-12-08 · Disposition to issuer · Disposed 18,500 · Balance 0 F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger"). F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted. F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Filing footnotes · ownership attribution and instrument terms

F1: On December 8, 2021, Thermo Fisher Scientific Inc., a Delaware corporation ("Buyer"), acquired the Issuer pursuant to a certain Agreement and Plan of Merger entered into by and among the Issuer, Buyer and Powder Acquisition Corp., a Delaware corporation and wholly-owned subsidiary of Buyer ("Merger Sub"), dated as of April 15, 2021 (the "Merger Agreement"). In accordance with the Merger Agreement, the Issuer merged with and into Merger Sub, with the Issuer surviving such merger as a wholly-owned subsidiary of Buyer (the "Merger").

F2: Includes 2,164 shares of common stock subject to a restricted stock unit grant (the "RSUs") which provided for vesting on the earlier of the one-year anniversary of the grant date and the date of the next regularly scheduled annual meeting of stockholders of the Issuer. At the effective time of the Merger, the RSUs were canceled and converted into the right to receive an amount of cash equal to the Merger Consideration (as defined below) multiplied by the number of restricted stock units being so canceled and converted.

F3: At the effective time of the Merger, each issued and outstanding share of the Issuer's common stock (other than certain excluded shares) automatically converted into the right to receive $47.50 in cash (the "Merger Consideration").

Terns Pharmaceuticals, Inc.

Report date May 05, 2026 · Filed May 05, 2026

Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.82	Direct	Reported balance After 2026-05-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.10	Direct	Reported balance After 2026-05-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-05 · Disposition to issuer · Disposed 45,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46	Direct	Reported balance After 2026-05-05 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-05-05 · Disposition to issuer · Disposed 10,657 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.85	Direct	Reported balance After 2026-05-05 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-05 · Disposition to issuer · Disposed 4,676 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.99	Direct	Reported balance After 2026-05-05 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.24	Direct	Reported balance After 2026-05-05 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-05 · Disposition to issuer · Disposed 28,475 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.72	Direct	Reported balance After 2026-05-05 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-05 · Disposition to issuer · Disposed 22,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.05	Direct	Reported balance After 2026-05-05 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-05 · Disposition to issuer · Disposed 32,000 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.60	Direct	Reported balance After 2026-05-05 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-05 · Disposition to issuer · Disposed 1,697 · Balance 0 F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price. F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Merger Agreement, at the Effective Time (as defined in the Merger Agreement), each option to purchase the Issuer's Shares that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was less than the Merger Consideration was cancelled and converted into the right to receive, without interest thereon and subject to the applicable withholding taxes, the excess of the Merger Consideration over the per share exercise price.

F2: On March 24, 2026, Terns Pharmaceuticals, Inc. (the "Issuer") entered into an Agreement and Plan of Merger (the "Merger Agreement") with Merck Sharp & Dohme LLC ("Merck") and Thailand Merger Sub, Inc. (the "Purchaser"), a wholly owned subsidiary of Merck. Pursuant to the Merger Agreement, the Purchaser completed a tender offer for the shares of the Issuer's common stock (the "Shares"). In exchange for each Share, tendering shareholders will receive $53.00 per Share (the "Merger Consideration"), payable in cash, net to the seller, and without interest, subject to any applicable withholding taxes, as described more fully in the Schedule 14D-9 filed by the Issuer on April 7, 2026.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 10, 2020 Filed Feb 12, 2020 21:17 UTC	PPD, Inc. PPD · Entity 15247	GrantCommon stock	93,595	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004253 · doc4.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,595 F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
February 10, 2020 Filed Feb 12, 2020 21:17 UTC	PPD, Inc. PPD · Entity 15247	Disposition to issuerNon-voting common stock	93,595	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-004253 · doc4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. F1 · price: Upon the completion of the initial public offering of PPD, Inc. (the "Issuer"), all shares of the Issuer's non-voting common stock automatically converted into shares of the Issuer's voting common stock on a one-for-one basis. Read SEC document
November 29, 2019 Filed Dec 3, 2019 21:34 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantDirector stock option (right to buy) · Derivative	35,000	$0.00 Strike: $2.18	$0.00	Disclosure SEC source: 0001562180-19-005800 · primarydocument.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,121 Underlying: Class A common stock · 35,000 shares Expires 2029-03-07 F1 · derivative.exercise_date: The option vests in three equal installments on each of the first three anniversaries of March 7, 2019. Read SEC document
May 22, 2019 Filed May 22, 2019 21:19 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-19-009672 · form4.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F3 · derivative.exercise_date: The RSUs were granted on May 22, 2018, and vested on the first anniversary of such date. F3 · derivative.expiration_date: The RSUs were granted on May 22, 2018, and vested on the first anniversary of such date. Read SEC document
May 22, 2019 Filed May 22, 2019 21:19 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionCommon Stock, Par Value $.0001 Per Share	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-19-009672 · form4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 21, 2019 Filed May 22, 2019 21:19 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-19-009672 · form4.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2 · derivative.exercise_date: The RSUs vest on the first anniversary of the grant date. F2 · derivative.expiration_date: The RSUs vest on the first anniversary of the grant date. Read SEC document
May 15, 2019 Filed May 17, 2019 19:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	3,971	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-19-000065 · wf-form4_155812301417639.xml · derivative · entry 4 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
May 15, 2019 Filed May 17, 2019 19:57 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	6,054	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-19-000065 · wf-form4_155812301417639.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,054 Underlying: Ordinary Shares · 6,054 shares Expires 2020-05-15 F2 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
May 15, 2019 Filed May 17, 2019 19:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	1,907	$49.55	$94,491.85	Disclosure SEC source: 0001585364-19-000065 · wf-form4_155812301417639.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,809 Read SEC document
May 15, 2019 Filed May 17, 2019 19:57 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	3,971	$49.55	$196,763.05	Disclosure SEC source: 0001585364-19-000065 · wf-form4_155812301417639.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,716 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Vesting of service-based restricted stock units granted on May 15, 2018. Read SEC document
March 23, 2019 Filed Mar 26, 2019 21:49 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionRestricted Stock Units · Derivative	7,911	$0.00	$0.00	Disclosure SEC source: 0001123292-19-000573 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,911 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vested in full on March 23, 2019. F2 · derivative.expiration_date: The restricted stock units vested in full on March 23, 2019. Read SEC document
March 23, 2019 Filed Mar 26, 2019 21:49 UTC	PRECIGEN, INC. XON · Entity 4356	Exercise / conversionCommon Stock	7,911	Not disclosed	Not disclosed	Disclosure SEC source: 0001123292-19-000573 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,040 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. Read SEC document
March 10, 2019 Filed Mar 11, 2019 20:06 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionRestricted Stock Units · Derivative	11,666	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001844 · primarydocument.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,667 Underlying: Class A Common Stock · 11,666 shares Expires 2020-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A Common Stock F3 · derivative.exercise_date: The restricted stock units were granted on March 10, 2017 and vest in three equal installments beginning March 10, 2018. Read SEC document
March 10, 2019 Filed Mar 11, 2019 20:06 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionClass A Common Stock	11,666	$0.00	$0.00	Disclosure SEC source: 0001562180-19-001844 · primarydocument.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Class A common stock issued upon vesting of 33.33% of the restricted stock units granted March 10, 2017. Read SEC document
March 08, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	42,450	$0.00 Strike: $5.06	$0.00	Disclosure SEC source: 0001123292-19-000468 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,450 Underlying: Common Stock · 42,450 shares Expires 2029-03-08 Read SEC document
March 08, 2019 Filed Mar 12, 2019 23:11 UTC	PRECIGEN, INC. XON · Entity 4356	GrantRestricted Stock Units · Derivative	24,703	$0.00	$0.00	Disclosure SEC source: 0001123292-19-000468 · edgar.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,614 Underlying: Common Stock · 24,703 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F2 · derivative.exercise_date: The restricted stock units vest in full one year from the grant date. F2 · derivative.expiration_date: The restricted stock units vest in full one year from the grant date. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:20 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	4,265	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-18-000048 · wf-form4_152849281294837.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:20 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	2,048	$73.22	$149,954.56	Disclosure SEC source: 0001585364-18-000048 · wf-form4_152849281294837.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,745 Read SEC document
June 06, 2018 Filed Jun 8, 2018 21:20 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	4,265	$73.22	$312,283.30	Disclosure SEC source: 0001585364-18-000048 · wf-form4_152849281294837.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 23, 2018 Filed May 23, 2018 20:28 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-18-025343 · form4.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F3 · derivative.exercise_date: The RSUs were granted on May 23, 2017, and vested on the first anniversary of such date. F3 · derivative.expiration_date: The RSUs were granted on May 23, 2017, and vested on the first anniversary of such date. Read SEC document
May 23, 2018 Filed May 23, 2018 20:28 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionCommon Stock, Par Value $.0001 Per Share	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-18-025343 · form4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
May 22, 2018 Filed May 23, 2018 20:28 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-18-025343 · form4.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2 · derivative.exercise_date: The RSUs vest on the first anniversary of the grant date. F2 · derivative.expiration_date: The RSUs vest on the first anniversary of the grant date. Read SEC document
May 15, 2018 Filed May 17, 2018 20:05 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	3,971	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-18-000032 · wf-form4_152658749282414.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,971 Underlying: Ordinary Shares · 3,971 shares Expires 2019-05-15 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:55 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	14,246	$0.00 Strike: $15.80	$0.00	Disclosure SEC source: 0001123292-18-000598 · edgar.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,246 Underlying: Common Stock · 14,246 shares Expires 2028-03-23 Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:55 UTC	PRECIGEN, INC. XON · Entity 4356	GrantRestricted Stock Units · Derivative	7,911	$0.00	$0.00	Disclosure SEC source: 0001123292-18-000598 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,911 Underlying: Common Stock · 7,911 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of XON common stock. F3 · derivative.exercise_date: The restricted stock units vest in full one year from the grant date. F3 · derivative.expiration_date: The restricted stock units vest in full one year from the grant date. Read SEC document
March 23, 2018 Filed Mar 29, 2018 21:55 UTC	PRECIGEN, INC. XON · Entity 4356	GrantCommon Stock	4,367	$15.80	$68,998.60	Disclosure SEC source: 0001123292-18-000598 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,129 F1 · price: The shares were issued to the reporting person in lieu of an annual retainer of $69,000. Read SEC document
March 10, 2018 Filed Mar 12, 2018 20:05 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionRestricted Stock Units · Derivative	11,667	$0.00	$0.00	Disclosure SEC source: 0001562180-18-001606 · primarydocument.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,333 Underlying: Class A Common Stock · 11,667 shares Expires 2020-03-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A Common Stock F3 · derivative.exercise_date: The restricted stock units were granted on March 10, 2017 and vests in three equal installments beginning March 10, 2018. Read SEC document
March 10, 2018 Filed Mar 12, 2018 20:05 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	Exercise / conversionClass A Common Stock	11,667	$0.00	$0.00	Disclosure SEC source: 0001562180-18-001606 · primarydocument.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of Class A common stock issued upon vesting of 33.33% of the restricted stock units granted March 10, 2017. Read SEC document
August 11, 2017 Filed Aug 15, 2017 17:15 UTC	PRECIGEN, INC. XON · Entity 4356	PurchaseCommon Stock	5,440	$18.32	$99,660.80	Disclosure SEC source: 0001225385-17-000103 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,762 Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:47 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionRestricted Stock Units · Derivative	1,017	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000127 · wf-form4_150092923531925.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 1,017 shares Expires 2017-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · kind: Vesting of service-based restricted stock units granted on June 06, 2017. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:47 UTC	PERRIGO Co plc PRGO · Entity 4516	Tax withholdingOrdinary Shares	489	$75.51	$36,924.39	Disclosure SEC source: 0001585364-17-000127 · wf-form4_150092923531925.xml · nonDerivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 528 Read SEC document
July 20, 2017 Filed Jul 24, 2017 20:47 UTC	PERRIGO Co plc PRGO · Entity 4516	Exercise / conversionOrdinary Shares	1,017	$75.51	$76,793.67	Disclosure SEC source: 0001585364-17-000127 · wf-form4_150092923531925.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 06, 2017 Filed Jun 8, 2017 21:41 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	1,017	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000109 · wf-form4_149695805592166.xml · derivative · entry 3 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017 Underlying: Ordinary Shares · 1,017 shares Expires 2017-07-20 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F2 · kind: Represents a prorated award for partial year of Board service. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
June 06, 2017 Filed Jun 8, 2017 21:41 UTC	PERRIGO Co plc PRGO · Entity 4516	GrantRestricted Stock Units · Derivative	4,265	Not disclosed	Not disclosed	Disclosure SEC source: 0001585364-17-000109 · wf-form4_149695805592166.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,265 Underlying: Ordinary Shares · 4,265 shares Expires 2018-06-06 F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. F1 · price: Each Restricted Stock Unit represents a contingent right to receive one Perrigo Company plc ordinary share. Read SEC document
May 23, 2017 Filed May 24, 2017 21:23 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	GrantRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-17-022173 · form4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2 · derivative.exercise_date: The RSUs vest on the first anniversary of the grant date. F2 · derivative.expiration_date: The RSUs vest on the first anniversary of the grant date. Read SEC document
May 17, 2017 Filed May 19, 2017 20:12 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionRestricted Stock Units · Derivative	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-17-021548 · form4.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock, par value $.0001 per share · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") converts into one share of common stock of SIGA Technologies, Inc. on a one for one basis. F2 · derivative.exercise_date: The RSUs were granted on May 17, 2016, and vested on the first anniversary of such date. F2 · derivative.expiration_date: The RSUs were granted on May 17, 2016, and vested on the first anniversary of such date. Read SEC document
May 17, 2017 Filed May 19, 2017 20:12 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionCommon Stock, Par Value $.0001 Per Share	15,000	$0.00	$0.00	Disclosure SEC source: 0001140361-17-021548 · form4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
March 16, 2017 Filed Mar 20, 2017 20:23 UTC	PRECIGEN, INC. XON · Entity 4356	GrantOption to Purchase Common Stock (Right to Buy) · Derivative	15,000	$0.00 Strike: $21.38	$0.00	Disclosure SEC source: 0001225385-17-000052 · edgar.xml · derivative · entry 2 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-03-16 Read SEC document
March 16, 2017 Filed Mar 20, 2017 20:23 UTC	PRECIGEN, INC. XON · Entity 4356	GrantCommon Stock	3,507	$0.00	$0.00	Disclosure SEC source: 0001225385-17-000052 · edgar.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,322 Read SEC document
March 10, 2017 Filed Mar 14, 2017 20:04 UTC	vTv Therapeutics Inc. VTVT · Entity 6614	GrantRestricted Stock Unit · Derivative	35,000	$0.00	$0.00	Disclosure SEC source: 0001562180-17-001256 · primarydocument.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Class A Common Stock · 35,000 shares Expires 2020-03-10 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of vTv Therapeutics Inc. Class A common stock. F2 · derivative.exercise_date: Grant vests in three equal annual installments beginning on March 10, 2018. Read SEC document
November 16, 2016 Filed Nov 18, 2016 21:28 UTC	SIGA TECHNOLOGIES INC SIGA · Entity 6205	Exercise / conversionCommon Stock, Par Value $.0001 Per Share	22,339	$33,508.50	$748,546,381.50	Disclosure SEC source: 0001140361-16-087258 · form4.xml · nonDerivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the exercise by the reporting person of such reporting person's basic subscription rights (each basic subscription right entitling the reporting person to purchase $0.65 worth of shares of SIGA Technologies, Inc.'s ("SIGA") common stock, par value $0.0001 per share, at a subscription price equal to $1.50 per share), issued pro rata to holders of SIGA common stock as of October 12, 2016 in a rights offering, as well as the shares of SIGA common stock received by the reporting person in connection with the reporting person's exercise of his oversubscription privilege. Read SEC document
December 15, 2010 Filed Dec 17, 2010 20:57 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	261	$17.08	$4,457.88	Disclosure SEC source: 0001225208-10-027361 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Former Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,194 Underlying: Common Stock · 261 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 30, 2010 Filed Dec 1, 2010 23:59 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	156	$16.30	$2,542.80	Disclosure SEC source: 0001225208-10-026039 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,933 Underlying: Common Stock · 156 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
November 15, 2010 Filed Nov 16, 2010 23:20 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	956	$16.75	$16,013.00	Disclosure SEC source: 0001225208-10-025013 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,777 Underlying: Common Stock · 956 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 29, 2010 Filed Nov 1, 2010 19:59 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	159	$17.42	$2,769.78	Disclosure SEC source: 0001225208-10-023788 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,821 Underlying: Common Stock · 159 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
October 15, 2010 Filed Oct 18, 2010 22:49 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	150	$17.75	$2,662.50	Disclosure SEC source: 0001225208-10-023185 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,662 Underlying: Common Stock · 150 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 30, 2010 Filed Oct 1, 2010 19:17 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	198	$17.17	$3,399.66	Disclosure SEC source: 0001225208-10-021672 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,512 Underlying: Common Stock · 198 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
September 15, 2010 Filed Sep 17, 2010 11:05 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	84	$17.27	$1,450.68	Disclosure SEC source: 0001225208-10-020971 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,314 Underlying: Common Stock · 84 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 31, 2010 Filed Sep 2, 2010 11:54 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	292	$15.91	$4,645.72	Disclosure SEC source: 0001225208-10-020178 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,230 Underlying: Common Stock · 292 shares Expires not disclosed F2 · derivative.exercise_price: Each unit represents one phantom share of common stock. F1 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F1 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document
August 13, 2010 Filed Aug 17, 2010 15:20 UTC	PFIZER INC PFE · Entity 2863	GrantPhantom Stock Units SSP · Derivative	860	$16.08	$13,828.80	Disclosure SEC source: 0001225208-10-019318 · doc4.xml · derivative · entry 1 KINDLER JEFFREY B · CIK 0001174454 · Director · Chairman & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,938 Underlying: Common Stock · 860 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.